



GENERAL INFORMATION

The Company's 2025 AGM was held on May 15, 2026, at the Company's head office, 27,330,100 shares of the Company were present in person or by proxy, representing 39.47% of the total shares of the Company (excluding the shares held by the Company and its subsidiaries). The Company's 2025 AGM was held on May 15, 2026, at the Company's head office, 27,330,100 shares of the Company were present in person or by proxy, representing 39.47% of the total shares of the Company (excluding the shares held by the Company and its subsidiaries). The Company's 2025 AGM was held on May 15, 2026, at the Company's head office, 27,330,100 shares of the Company were present in person or by proxy, representing 39.47% of the total shares of the Company (excluding the shares held by the Company and its subsidiaries).

The Company's 2025 AGM was held on May 15, 2026, at the Company's head office, 27,330,100 shares of the Company were present in person or by proxy, representing 39.47% of the total shares of the Company (excluding the shares held by the Company and its subsidiaries). The Company's 2025 AGM was held on May 15, 2026, at the Company's head office, 27,330,100 shares of the Company were present in person or by proxy, representing 39.47% of the total shares of the Company (excluding the shares held by the Company and its subsidiaries).

The Company's 2025 AGM was held on May 15, 2026, at the Company's head office, 27,330,100 shares of the Company were present in person or by proxy, representing 39.47% of the total shares of the Company (excluding the shares held by the Company and its subsidiaries). The Company's 2025 AGM was held on May 15, 2026, at the Company's head office, 27,330,100 shares of the Company were present in person or by proxy, representing 39.47% of the total shares of the Company (excluding the shares held by the Company and its subsidiaries).

The Company's 2025 AGM was held on May 15, 2026, at the Company's head office, 27,330,100 shares of the Company were present in person or by proxy, representing 39.47% of the total shares of the Company (excluding the shares held by the Company and its subsidiaries). The Company's 2025 AGM was held on May 15, 2026, at the Company's head office, 27,330,100 shares of the Company were present in person or by proxy, representing 39.47% of the total shares of the Company (excluding the shares held by the Company and its subsidiaries).

POTENTIAL ACQUISITION

On May 18, 2026, the Board of Directors of the Company held a meeting and decided to acquire the shares of the Company's subsidiary, G. I. e. e. a. a. c. de a. f. RMB31.45. The Company's 2025 AGM was held on May 15, 2026, at the Company's head office, 27,330,100 shares of the Company were present in person or by proxy, representing 39.47% of the total shares of the Company (excluding the shares held by the Company and its subsidiaries).

Part 1: (1) The Company's 2025 AGM was held on May 15, 2026, at the Company's head office, 27,330,100 shares of the Company were present in person or by proxy, representing 39.47% of the total shares of the Company (excluding the shares held by the Company and its subsidiaries).

(2) G. I. e. e. a. a. c. de a. f. RMB31.45.

Part 2: The Company's 2025 AGM was held on May 15, 2026, at the Company's head office, 27,330,100 shares of the Company were present in person or by proxy, representing 39.47% of the total shares of the Company (excluding the shares held by the Company and its subsidiaries).

The P e : The P e ca ed a F 12 15, P a e II, H e
Ed ca Pa B e Ce e , C a a S bd c , O a
D c , We C , Z e a P ce, e PRC, a
f a ea f 4,523.86 . . a d a d e a ea f 267.90
. . T e a ed e f e P e a d f acc da
a d ca e / e , a d e e f e a d e
e e 29 Ja a 2043. T e P e de e ed b G da
I e e , e ef e e a c a e c f e P e
G da I e e a cab e.

A a e a bee ce a ed e e P e , S a a
P d De e e Ba C ., L d. We B a c be e
a ee. T e af e e ed a e a be e ea ed
e e f e P e .

A a e da e f a ce e , e P e -
ed b G da I e e .

De e a d e a f U e C a f a e f e c de a de e
a fe f e: P e P c a e A ee e , e P e a be de e ed
e C a a a - ba e eed f a f a
a d e ced e . G da I e e a a e
de e e C a e ce f ca e f a d e a d
b d e , a e a e e c a e ce
e ec f e P e . T e C a a a de e e a
f a fe f e f e P e .

W effec f e da e f de e f e P e , a e
e ce- e a ed e e e a be b e b e C a , a d a
f da a e, a d a e a a be b e b
e C a .

PAYMENT TERMS AND BASIS FOR DETERMINING THE CONSIDERATION

T e a c de a f e ac f e P e RMB31.45 (c e f a).
T e c de a a de e ed af e a e e a be ee e a e ba ed e
fa a e a e, efe e ce e a a f e P e f RMB35,286,000 c d c ed b
e de e de e a e , A a-Pac f c C a d A a a L ed (e **Independent**
Valuer), ba ed e a a ed a e a e f e P e a a 30 A 2026 e
a e c a a ac . T e C a c de ef e f e a a e
e ec f e P e e c c a f e AGM. T e c a c e f e a a e
a e a f :

Valuation Date

30 A 2026

Basis of Valuation

The Independent Valuer has carried out a detailed analysis of the available data and has concluded that the value of the property is determined by the market value of the property as a whole, taking into account the location, size, and condition of the property.

Methods of Valuation

The Independent Valuer has used the following methods of valuation: the comparison method, the cost method, and the income method. The comparison method involves comparing the property with similar properties in the market. The cost method involves estimating the cost of the property, including the cost of the land, the cost of the building, and the cost of the fittings. The income method involves estimating the income that the property can generate.

Valuation Assumptions

The Independent Valuer has made the following assumptions in carrying out the valuation: the property is in good condition, the property is used for its intended purpose, and the market is stable.

The Independent Valuer has also made the following assumptions: the property is free from any encumbrances, the property is not subject to any special rates or taxes, and the property is not subject to any other restrictions.

Valuation Standards

The Independent Valuer has followed the standards set out in the RICS Valuation Standards, the HKIS Valuation Standards, and the International Valuation Standards.

Conclusion of Value

The Independent Valuer has concluded that the value of the property is RMB35,286,000.

In addition, the Independent Valuer has also concluded that the value of the property is RMB90 million, which is equivalent to RMB407,147.4.

The Independent Valuer has also concluded that the value of the property is 50% of the value of the property as a whole.

The academy of the people befuddled by the evidence
for the cause.

ONLINE SIGNING

Sa e a d c ed ab e, a a e da e f a ce e , e be ed e a d be ef
f e D ec a ade a ea ab e e e , S a e de e ed ab a f
e e e a e a e e P e a Ac a e AGM.

A c c a c a , a e , () f e de a f e P e a Ac ; () a
e e f e I de e de B a d C ee e I de e de S a e de (e
ec e da f e I de e de B a d C ee); () a e e f ad ce f G a Ca a
e I de e de B a d C ee a d e I de e de S a e de ; () e e a a
e ; a d () a ce f e AGM, be b ed e eb e f e S c E c a e
(. e e .) a d e eb e f e C a (. .c), a d d a c ed e
de f H S a e f e C a acc da ce e c e ea f e ce f c a e
c ca , c a ce e a cab e L R e .

A add a e e ed f a e ce a f a be c ded e c c a , e
C a e ec b a d/ d a c e c c a e a e e ab e bef e 9
J e 2026.

DEFINITIONS

I a ce e , e e c e e e e e , ef e e a a e
e f ea :

AGM e 2025 a a e e a ee f e C a be c e ed
d e c e

B a d e b a d f d ec f e C a

C a We ❷ Ka H a C ., L d. (溫州康寧醫院股份有限公
司), a c ed c a e ab ed de e a f
e PRC, e H S a e f c a e ed e a b a d f e
S c E c a e (c c de: 2120)

c ec ed e () a e ea a c bed de e L R e

c ec ed a ac () a e ea a c bed de e L R e

D ec () e d ec () f e C a

G da I e e We ❷ G da I e e C ., L d. (溫州國大投資有限公司),
a ed ab c a c a ed e PRC, e a e
be ef c a e f c M . GUAN We

H S a e () e ea ed f e a e () e a e ca a f e C a
a a a e f RMB1.00 eac , c a e ed a d aded
e a b a d f e S c E c a e

H K e H K S ec a Ad a e Re f e PRC

I de e de B a d e de e de b a d c ee c a e de e de
C ee -e ec e D ec (a e , M . ZHONG We a , M . JIN
L a d M . CHAN Sa Ke H), e ab ed ad e e
I de e de S a e de e ec f e P e a Ac

I de e de F a c a	G a Ca a L ed, a ce ed c a ca e
Ad e	6 (ad c a e f a ce) e a ed ac de e
G a Ca a	Sec e a d F e O d a ce (C a e 571 f e La f H
	K), a a ed a e I de e de F a c a Ad e ad e
	e I de e de B a d C ee a d e I de e de S a e de
	e ec f e P e a Ac

de e de -e ec e e de e de -e ec e D ec () f e C a
D ec ()

I de e de	S a e de () a e e ed ab a f a e
S a e de ()	AGM e ec f e a a f e P e a Ac

L R e	e R e G e e L f Sec e T e S c
	E c a e f H K L ed, a a e ded, e e ed
	e e d f e d f e e

e	acc d e e e a e a f e We M c a
	G e e f Z e a P ce, e PRC, e a e a d c a e f
	c e c a e e b ec e a d f
	e e e a e e e c bed b e e e .

PRC C a	e Pe e' Re b c f C a, f e e f a ce e ,
	e c de H K , e Maca S ec a Ad a e Re f e
	PRC a d Ta a

P e P c a e	e P e P c a e A ee e be e e ed be ee e
A ee e	C a a d G da I e e

P e a Ac	e ed c a e f e P e b e C a f G da
	I e e

RMB	e a f c e c f e PRC
-----	---------------------

SFO	e Sec e a d F e O d a ce (C a e 571 f e La f
	H K), a a e ded, e e ed e e d f e d f
	e e

S a e ()	e a e () f e C a , c d d e c S a e () a d H
	S a e ()

S a e de ()	de () f e S a e ()
--------------	----------------------

S c E c a e	T e S c E c a e f H K L ed
-------------	----------------------------

. .	a e e e
-----	---------

e P e e e ca ed a F 12 15, P a e II, H e Ed ca
Pa B e Ce e , C a a S bd c , O a D c , We
C , Z e a P ce, e PRC

ea a e() a e ea a c bed de e L R e

B e f e B a d
Wenzhou Kangning Hospital Co., Ltd.
GUAN Weili